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cell carcinomas, or with atypical carcinoids, may be ap-
proached initially as having aggressive disease. Somatosta-
tin analogues play a cytostatic role in indolent tumors, and 
chemotherapy may play a role against other, more aggres-
sive NETs. Obviously, there is an urgent need for novel thera-
pies that are effective against NETs. 
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 Introduction 
 A panel of experts from four Latin-American and two 
European countries convened in São Paulo, Brazil, in 
May of 2007, for a consensus meeting on the management 
of neuroendocrine tumors (NETs) of the gastrointestinal 
tract and pancreas. This paper presents the opinions of 
the panelists on subjects related to the classification, di-
agnosis, treatment and follow-up of patients with NETs 
in Latin America, a world region that currently compris-
es approximately 550 million inhabitants. Given the fact 
that prospective data from controlled trials for many of 
the questions discussed in the meeting are currently 
scarce  [1] , evidence-based medical data have been used by 
panel members whenever possible, but many of the rec-
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 Abstract 
 A panel of experts from Latin America convened in Brazil, in 
May of 2007, for consensus recommendations regarding the 
management of neuroendocrine tumors (NETs) of the gas-
trointestinal tract and pancreas. The recently introduced 
World Health Organization classification of NETs represents 
a step forward, but the former classification of carcinoids 
into foregut, midgut and hindgut is still likely to be useful in 
the near future. Macroscopic description of the tumor should 
be followed by light microscopic examination and immuno-
histochemical staining, whereas other techniques might not 
be widely available in Latin America. Surgery remains the 
mainstay of treatment for patients with potentially curable 
tumors, and adequate selection is paramount in order to op-
timize treatment results. Regarding systemic therapy, pa-
tients with well-differentiated tumors or islet-cell carcino-
mas may be categorized as having indolent disease, while 
patients with poorly differentiated, anaplastic, and small-
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